Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blood-derived myeloid and plasmacytoid dendritic cell vaccination in stage III melanoma
NL-OMON42306Active, not recruiting
- Sponsor
- Tumor Immunologie
- Start
- Oct 2015
- Countries
- 1
01
Overview
Open-label trial in melanoma (3 arms), sponsored by Tumor Immunologie. Primary endpoints: Immunogenicity: type I interferon response, Immunogenicity: KLH responses and 1 more. Started Oct 2015; status: active, not recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON42306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42306.